# Evaluating Celecoxib Activity in Mycobacterium Tuberculosis: A Whole Blood Bactericidal Activity Study in Healthy Volunteers

> **NCT02602509** · PHASE1 · COMPLETED · sponsor: **National University Hospital, Singapore** · enrollment: 18 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** Celecoxib
- **DRUG:** Rifampicin
- **DRUG:** Pyrazinamide

## Key facts

- **NCT ID:** NCT02602509
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2017-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02602509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02602509, "Evaluating Celecoxib Activity in Mycobacterium Tuberculosis: A Whole Blood Bactericidal Activity Study in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02602509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*